Table 2.
Univariate analysis according to sex in ICH patients (n = 961).
| Male (n = 549) | Female (n = 412) | p-value | |
|---|---|---|---|
| DEMOGRAPHIC VARIABLES | |||
| Age (years) | 71.1 ± 12.8 | 76.2 ± 13.1 | <0.0001 |
| History of hypertension, % | 59.0 | 61.9 | 0.387 |
| History of diabetes mellitus, % | 21.5 | 18.7 | 0.293 |
| History of alcoholism, % | 22.0 | 5.8 | <0.0001 |
| History of smoking, % | 15.8 | 3.9 | <0.0001 |
| History of dyslipidemia, % | 34.1 | 38.8 | 0.136 |
| Peripheral arterial disease, % | 6.4 | 1.5 | <0.0001 |
| Previous ischemic heart disease, % | 11.1 | 4.4 | <0.0001 |
| Ischemic heart disease, % | 2.7 | 4.1 | 0.233 |
| Atrial fibrillation, % | 15.1 | 20.4 | 0.033 |
| Previous transient ischemic attack, % | 1.5 | 3.2 | 0.075 |
| History of Ischemic stroke, % | 7.8 | 9.7 | 0.509 |
| History of Intracerebral hemorrhage, % | 9.1 | 10 | 0.509 |
| Anticoagulants, % | 11.5 | 16.5 | 0.025 |
| Antiaggregants, % | 16.6 | 14.8 | 0.457 |
| Stroke on awakening, % | 4.9 | 4.4 | 0.759 |
| CLINICAL VARIABLES | |||
| Previous mRS | 0 [0, 1] | 1 [0, 1] | <0.0001 |
| Time from stroke onset (minutes) | 212.7 ± 198.2 | 285.4 ± 256.2 | <0.0001 |
| NIHSS score at admission | 12 [7, 16] | 13 [8, 18] | 0.003 |
| Early neurological deterioration, % | 27.3 | 26.9 | 0.942 |
| Etiology | 0.008 | ||
| Hypertensive, % | 50.6 | 46.6 | |
| Amyloid, % | 4.9 | 9.0 | |
| Anticoagulants, % | 11.7 | 16.3 | |
| Others / Undetermined, % | 32.8 | 28.2 | |
| Hematoma volume at admission (mL) | 42.1 ± 37.6 | 41.2 ± 32.8 | 0.934 |
| Hematoma volume 4th−7th day (mL) | 46.2 ± 43.5 | 45.2 ± 35.5 | 0.767 |
| Total hematoma volume (mL) | 61.5 ± 52.4 | 58.0 ± 41.4 | 0.418 |
| Volume of hypodensity (mL) | 15.2 ± 20.1 | 12.8 ± 15.4 | 0.129 |
| Hematoma growth (mL) | 14.1 ± 30.9 | 6.4 ± 26.1 | 0.001 |
| Topography | 0.389 | ||
| Deep hemispheric, % | 53.8 | 48.1 | |
| Lobar, % | 35.2 | 41.5 | |
| Cerebellar, % | 5.1 | 4.9 | |
| Breinstem, % | 3.8 | 3.9 | |
| Primary intraventricular, % | 2.0 | 1.7 | |
| Axillary temperature at admission (°C) | 36.5 ± 0.7 | 36.4 ± 0.7 | 0.276 |
| Blood glucose at admission (mg/dL) | 129.6 ± 38.1 | 137.7 ± 49.21 | 0.220 |
| Sedimentation rate (mm) | 22.5 ± 19.8 | 26.9 ± 23.4 | 0.904 |
| Glycosylated hemoglobin, % | 5.7 ± 0.8 | 5.8 ± 0.9 | 0.909 |
| SBP at admission (mmHg) | 167.4 ± 42.1 | 165.8 ± 39.6 | 0.612 |
| DBP at admission (mmHg) | 86.2 ± 20.5 | 89.3 ± 21.6 | 0.403 |
| LDL cholesterol (mg/dL) | 106.5 ± 35.3 | 115.9 ± 38.0 | 0.021 |
| HDL cholesterol (mg/dL) | 37.1 ± 19.7 | 40.8 ± 19.6 | <0.0001 |
| Triglycerides (mg/dL) | 96.6 ± 46.8 | 105.2 ± 43.1 | 0.303 |
| MOLECULAR MARKERS | |||
| Leukocytes at admission (×103/mL) | 8.7 ± 3.4 | 9.0 ± 2.8 | 0.308 |
| Fibrinogen at admission, mg/dL | 422.9 ± 92.7 | 468.2 ± 99.8 | <0.0001 |
| C-reactive protein at admission (mg/dL) | 5.0 ± 5.1 | 5.1 ± 4.5 | 0.300 |
| Microalbuminuria (mg/24 h) | 20.8 ± 38.3 | 16.1 ± 21.9 | 0.131 |
| NT-proBNP levels (pg/mL) | 850.6 ± 1235.5 | 934.8 ± 1508.08 | 0.229 |
| OUTCOME | |||
| mRS at 3-months | 3 [1, 6] | 3 [2, 6] | 0.078 |
| Poor outcome, % | 56.8 | 61.9 | 0.127 |